{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:09:09Z","timestamp":1787857749317,"version":"build-2784847793"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-15070-3","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:45:17Z","timestamp":1761734717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Study of the association between HDAC8, SIRT1, and P53 gene expression with drug resistance in chronic myeloid leukemia patients"],"prefix":"10.1186","volume":"25","author":[{"given":"Rojin","family":"Mansouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Heydarpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8592-7651","authenticated-orcid":false,"given":"Kheirollah","family":"Yari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Naseroleslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Payandeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"4","key":"15070_CR1","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41375-019-0647-x","volume":"34","author":"IS Pagani","year":"2020","unstructured":"Pagani IS, Dang P, Saunders VA, Grose R, Shanmuganathan N, Kok CH, Carne L, Rwodzi Z, Watts S, McLean J. Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. Leukemia. 2020;34(4):1052\u201361.","journal-title":"Leukemia"},{"key":"15070_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fonc.2019.00603","volume":"9","author":"V Garcia-Gutierrez","year":"2019","unstructured":"Garcia-Gutierrez V, Hernandez-Boluda J. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol. 2019;9:603.","journal-title":"Front Oncol"},{"issue":"1","key":"15070_CR3","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1186\/s12885-024-12102-2","volume":"24","author":"JW Kuan","year":"2024","unstructured":"Kuan JW, Su AT, Sim S-P, Tay SP. Higher prevalence of harbouring BCR::ABL1 in first-degree relatives of chronic myeloid leukaemia (CML) patients compared to normal population. BMC Cancer. 2024;24(1):734.","journal-title":"BMC Cancer"},{"key":"15070_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01106-1","volume":"14","author":"K Saxena","year":"2021","unstructured":"Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, Daver N, Kadia T, DiNardo CD, Konopleva M. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol. 2021;14:1\u201310.","journal-title":"J Hematol Oncol"},{"key":"15070_CR5","doi-asserted-by":"publisher","first-page":"100968","DOI":"10.1016\/j.blre.2022.100968","volume":"56","author":"JH Lipton","year":"2022","unstructured":"Lipton JH, Br\u00fcmmendorf TH, Gambacorti-Passerini C, Garcia-Guti\u00e9rrez V, Deininger MW, Cortes JE. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia-What to look for when treatment-free remission is not an option. Blood Rev. 2022;56:100968.","journal-title":"Blood Rev"},{"issue":"14","key":"15070_CR6","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.3390\/cancers14143300","volume":"14","author":"G Poudel","year":"2022","unstructured":"Poudel G, Tolland MG, Hughes TP, Pagani IS. Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia. Cancers. 2022;14(14):3300.","journal-title":"Cancers"},{"issue":"12","key":"15070_CR7","first-page":"1595","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood J Am Soc Hematol. 2017;129(12):1595\u2013606.","journal-title":"Blood J Am Soc Hematol"},{"issue":"7","key":"15070_CR8","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1172\/JCI127080","volume":"129","author":"A Abraham","year":"2019","unstructured":"Abraham A, Qiu S, Chacko BK, Li H, Paterson A, He J, Agarwal P, Shah M, Welner R, Darley-Usmar VM. SIRT1 regulates metabolism and leukemogenic potential in CML stem cells. J Clin Investig. 2019;129(7):2685\u2013701.","journal-title":"J Clin Investig"},{"issue":"19","key":"15070_CR9","doi-asserted-by":"publisher","first-page":"14470","DOI":"10.3390\/ijms241914470","volume":"24","author":"GR Fajardo-Ordu\u00f1a","year":"2023","unstructured":"Fajardo-Ordu\u00f1a GR, Ledesma-Mart\u00ednez E, Agui\u00f1iga-Sanchez I, Weiss-Steider B, Santiago-Osorio E. Role of SIRT1 in chemoresistant leukemia. Int J Mol Sci. 2023;24(19):14470.","journal-title":"Int J Mol Sci"},{"key":"15070_CR10","doi-asserted-by":"crossref","unstructured":"Fajardo-Ordu\u00f1a GR, Ledesma-Mart\u00ednez E, Agui\u00f1iga-Sanchez I, Weiss-Steider B, Santiago-Osorio E. Role of SIRT1 in Chemoresistant Leukemia. Int J Mol Sci 2023, 24(19).","DOI":"10.3390\/ijms241914470"},{"issue":"9","key":"15070_CR11","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ncb1468","volume":"8","author":"C Wang","year":"2006","unstructured":"Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y, Nemoto S, Finkel T, Gu W, Cress WD. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol. 2006;8(9):1025\u201331.","journal-title":"Nat Cell Biol"},{"issue":"10","key":"15070_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S0968-0004(00)89093-3","volume":"20","author":"T Enoch","year":"1995","unstructured":"Enoch T, Norbury C. Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends Biochem Sci. 1995;20(10):426\u201330.","journal-title":"Trends Biochem Sci"},{"issue":"10","key":"15070_CR13","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/s12276-022-00863-4","volume":"54","author":"Y Abuetabh","year":"2022","unstructured":"Abuetabh Y, Wu HH, Chai C, Al Yousef H, Persad S, Sergi CM, Leng R. DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities. Exp Mol Med. 2022;54(10):1658\u201369.","journal-title":"Exp Mol Med"},{"issue":"2","key":"15070_CR14","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","volume":"21","author":"L Li","year":"2012","unstructured":"Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, Holyoake TL, Chen W, Bhatia R. Activation of p53 by SIRT1 Inhibition enhances elimination of CML leukemia stem cells in combination with Imatinib. Cancer Cell. 2012;21(2):266\u201381.","journal-title":"Cancer Cell"},{"issue":"19","key":"15070_CR15","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.3390\/cells11193161","volume":"11","author":"JY Kim","year":"2022","unstructured":"Kim JY, Cho H, Yoo J, Kim GW, Jeon YH, Lee SW, Kwon SH. Pathological role of HDAC8: cancer and beyond. Cells. 2022;11(19):3161.","journal-title":"Cells"},{"issue":"6","key":"15070_CR16","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872\u201384.","journal-title":"Blood"},{"issue":"1","key":"15070_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s43042-022-00379-6","volume":"24","author":"N Nouri","year":"2023","unstructured":"Nouri N, Mehrzad V, Khalaj Z, Zaker E, Zare F, Abbasi E, Khosravi M, Kalantar SM, Salehi M. Effects of ABCG2 C421A and ABCG2 G34A genetic polymorphisms on clinical outcome and response to Imatinib mesylate, in Iranian chronic myeloid leukemia patients. Egypt J Med Hum Genet. 2023;24(1):1.","journal-title":"Egypt J Med Hum Genet"},{"issue":"4","key":"15070_CR18","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384.","journal-title":"Leukemia"},{"issue":"02","key":"15070_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4103\/2096-2924.242756","volume":"2","author":"W Xu","year":"2018","unstructured":"Xu W, Zhang N, Li L-S, Wang Y, Wang L, Du M-R, Li D-J, Sun Y. Gene expression pattern of histone acetylation enzymes changed in the hypothalamus of middle-aged female rats: A putative mechanism for female reproductive aging. Reproductive Dev Med. 2018;2(02):65\u201373.","journal-title":"Reproductive Dev Med"},{"issue":"4","key":"15070_CR20","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1128\/JVI.01757-06","volume":"81","author":"CE Petre","year":"2007","unstructured":"Petre CE, Sin S-H, Dittmer DP. Functional p53 signaling in kaposi\u2019s sarcoma-associated herpesvirus lymphomas: implications for therapy. J Virol. 2007;81(4):1912\u201322.","journal-title":"J Virol"},{"issue":"7","key":"15070_CR21","first-page":"1324","volume":"49","author":"KG Samani","year":"2020","unstructured":"Samani KG, Farrokhi E, Tabatabaee A, Jalilian N, Jafari M. Synergistic effects of Lauryl gallate and Tamoxifen on human breast cancer cell. Iran J Public Health. 2020;49(7):1324.","journal-title":"Iran J Public Health"},{"key":"15070_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12935-018-0523-1","volume":"18","author":"DDA Rabello","year":"2018","unstructured":"Rabello DDA, Ferreira V, Berzoti-Coelho MG, Burin SM, Magro CL, Cacemiro MDC, Sim\u00f5es BP, Saldanha-Araujo F, de Castro FA, Pittella-Silva F. MLL2\/KMT2D and MLL3\/KMT2C expression correlates with disease progression and response to Imatinib mesylate in chronic myeloid leukemia. Cancer Cell Int. 2018;18:26.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"15070_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1152\/physiolgenomics.00025.2005","volume":"21","author":"RD Barber","year":"2005","unstructured":"Barber RD, Harmer DW, Coleman RA, Clark BJ. GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues. Physiol Genomics. 2005;21(3):389\u201395.","journal-title":"Physiol Genomics"},{"issue":"1","key":"15070_CR24","doi-asserted-by":"publisher","first-page":"bpae098","DOI":"10.1093\/biomethods\/bpae098","volume":"10","author":"Z Sadaqat","year":"2025","unstructured":"Sadaqat Z, Joseph S, Verma C, Muni Reddy J, Prakash A, Thomas T, Bharadwaj V, Vyas N. Real time-PCR a diagnostic tool for reporting copy number variation and relative gene-expression changes in pediatric B-cell acute lymphoblastic leukemia-a pilot study. Biol Methods Protoc. 2025;10(1):bpae098.","journal-title":"Biol Methods Protoc"},{"issue":"10","key":"15070_CR25","doi-asserted-by":"publisher","first-page":"901","DOI":"10.7150\/ijms.4655","volume":"9","author":"M Narita","year":"2012","unstructured":"Narita M, Saito A, Kojima A, Iwabuchi M, Satoh N, Uchiyama T, Yamahira A, Furukawa T, Sone H, Takahashi M. Quantification of BCR-ABL mRNA in plasma\/serum of patients with chronic myelogenous leukemia. Int J Med Sci. 2012;9(10):901\u20138.","journal-title":"Int J Med Sci"},{"key":"15070_CR26","doi-asserted-by":"crossref","unstructured":"Asif M, Hussain A, Wali A, Ahmed N, Ali I, Iqbal Z, Amir M, Shafiq M, Rasool M. Molecular, Cytogenetic, and Hematological Analysis of Chronic Myeloid Leukemia Patients and Discovery of Two Novel Translocations. Anal Cell Pathol (Amst) 2021, 2021:4909012.","DOI":"10.1155\/2021\/4909012"},{"issue":"4","key":"15070_CR27","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3892\/etm.2015.2712","volume":"10","author":"KR Rogers-Broadway","year":"2015","unstructured":"Rogers-Broadway KR, Karteris E. Amplification efficiency and thermal stability of qPCR instrumentation: current landscape and future perspectives. Exp Ther Med. 2015;10(4):1261\u20134.","journal-title":"Exp Ther Med"},{"key":"15070_CR28","doi-asserted-by":"crossref","unstructured":"Melo JV, Goldman JM, Goldman JM, Daley GQ. Chronic myeloid leukemia\u2014a brief history. Myeloproliferative Disorders. 2007;1\u201313.","DOI":"10.1007\/978-3-540-34506-0_1"},{"issue":"2","key":"15070_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5045\/br.2022.2021173","volume":"57","author":"MA Samad","year":"2022","unstructured":"Samad MA, Mahboob E, Mansoor H. Chronic myeloid leukemia: a type of MPN. Blood Res. 2022;57(2):95\u2013100.","journal-title":"Blood Res"},{"issue":"3","key":"15070_CR30","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018;93(3):442\u201359.","journal-title":"Am J Hematol"},{"key":"15070_CR31","doi-asserted-by":"crossref","unstructured":"Wang L, Li L, Chen R, Huang X, Ye X. Understanding and monitoring chronic myeloid leukemia blast crisis: how to better manage patients. Cancer Manage Res 2021:4987\u20135000.","DOI":"10.2147\/CMAR.S314343"},{"issue":"2","key":"15070_CR32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5306\/wjco.v12.i2.69","volume":"12","author":"MM Sampaio","year":"2021","unstructured":"Sampaio MM, Santos MLC, Marques HS, Gon\u00e7alves VLS, Ara\u00fajo GRL, Lopes LW, Apolonio JS, Silva CS, Santos LKS, Cuzzuol BR, et al. Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review. World J Clin Oncol. 2021;12(2):69\u201394.","journal-title":"World J Clin Oncol"},{"key":"15070_CR33","doi-asserted-by":"publisher","first-page":"742802","DOI":"10.3389\/fgene.2021.742802","volume":"12","author":"M Amir","year":"2021","unstructured":"Amir M, Javed S. A review on the therapeutic role of TKIs in case of CML in combination with epigenetic drugs. Front Genet. 2021;12:742802.","journal-title":"Front Genet"},{"key":"15070_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1756-8722-3-47","volume":"3","author":"G Wei","year":"2010","unstructured":"Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or Imatinib. J Hematol Oncol. 2010;3:47.","journal-title":"J Hematol Oncol"},{"key":"15070_CR35","doi-asserted-by":"crossref","unstructured":"Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014(1).","DOI":"10.1155\/2014\/357027"},{"issue":"6","key":"15070_CR36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/PPO.0b013e318237e5b7","volume":"17","author":"DW Woessner","year":"2011","unstructured":"Woessner DW, Lim CS, Deininger MW. Development of an effective therapy for chronic myelogenous leukemia. Cancer J. 2011;17(6):477\u201386.","journal-title":"Cancer J"},{"issue":"13","key":"15070_CR37","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.3390\/cancers16132478","volume":"16","author":"P Garg","year":"2024","unstructured":"Garg P, Malhotra J, Kulkarni P, Horne D, Salgia R, Singhal SS. Emerging therapeutic strategies to overcome drug resistance in cancer cells. Cancers. 2024;16(13):2478.","journal-title":"Cancers"},{"key":"15070_CR38","doi-asserted-by":"crossref","unstructured":"Alves R, Gon\u00e7alves AC, Rutella S, Almeida AM, De Las Rivas J, Trougakos IP, Sarmento Ribeiro AB. Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia-From Molecular Mechanisms to Clinical Relevance. Cancers (Basel) 2021, 13(19).","DOI":"10.3390\/cancers13194820"},{"key":"15070_CR39","doi-asserted-by":"crossref","unstructured":"Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med 2016, 6(10).","DOI":"10.1101\/cshperspect.a026831"},{"key":"15070_CR40","doi-asserted-by":"crossref","unstructured":"Amin SA, Khatun S, Gayen S, Das S, Jha T. Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)? Eur J Med Chem 2023:115594.","DOI":"10.1016\/j.ejmech.2023.115594"},{"issue":"4","key":"15070_CR41","first-page":"184","volume":"7","author":"S Abbasian","year":"2015","unstructured":"Abbasian S, Ghotaslou A, Ghasemi A, Nadali F. Analysis of expression of SIRT1 gene in patients with chronic myeloid leukemia resistant to Imatinib mesylate. Iran J Blood Cancer. 2015;7(4):184\u201390.","journal-title":"Iran J Blood Cancer"},{"issue":"1","key":"15070_CR42","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/mnfr.201300195","volume":"58","author":"VBO Ayissi","year":"2014","unstructured":"Ayissi VBO, Ebrahimi A, Schluesenner H. Epigenetic effects of natural polyphenols: A focus on SIRT1-mediated mechanisms. Mol Nutr Food Res. 2014;58(1):22\u201332.","journal-title":"Mol Nutr Food Res"},{"key":"15070_CR43","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3389\/fcell.2020.00844","volume":"8","author":"M Spreafico","year":"2020","unstructured":"Spreafico M, Gruszka AM, Valli D, Mazzola M, Deflorian G, Quint\u00e8 A, Totaro MG, Battaglia C, Alcalay M, Marozzi A, et al. HDAC8: A promising therapeutic target for acute myeloid leukemia. Front Cell Dev Biol. 2020;8:844.","journal-title":"Front Cell Dev Biol"},{"key":"15070_CR44","doi-asserted-by":"crossref","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Al-Buhadilly AK. p53 gene (NY-CO-13) levels in patients with chronic myeloid leukemia: the role of Imatinib and nilotinib. Diseases 2018, 6(1).","DOI":"10.3390\/diseases6010013"},{"issue":"1","key":"15070_CR45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/diseases6010013","volume":"6","author":"HM Al-Kuraishy","year":"2018","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Al-Buhadilly AK. p53 gene (NY-CO-13) levels in patients with chronic myeloid leukemia: the role of Imatinib and nilotinib. Diseases. 2018;6(1):13.","journal-title":"Diseases"},{"issue":"5","key":"15070_CR46","doi-asserted-by":"publisher","first-page":"8921","DOI":"10.18632\/oncotarget.13475","volume":"8","author":"K Hientz","year":"2016","unstructured":"Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2016;8(5):8921.","journal-title":"Oncotarget"},{"key":"15070_CR47","doi-asserted-by":"publisher","first-page":"101073","DOI":"10.1016\/j.jbior.2024.101073","volume":"95","author":"JA McCubrey","year":"2025","unstructured":"McCubrey JA, Follo MY, Ratti S, Martelli AM, Manzoli L, Augello G, Cervello M, Cocco L. TP53 gene status can promote sensitivity and resistance to chemotherapeutic drugs and small molecule signal transduction inhibitors. Adv Biol Regul. 2025;95:101073.","journal-title":"Adv Biol Regul"},{"issue":"22","key":"15070_CR48","doi-asserted-by":"publisher","first-page":"8990","DOI":"10.1073\/pnas.1100600108","volume":"108","author":"X-P Zhang","year":"2011","unstructured":"Zhang X-P, Liu F, Wang W. Two-phase dynamics of p53 in the DNA damage response. Proc Natl Acad Sci. 2011;108(22):8990\u20135.","journal-title":"Proc Natl Acad Sci"},{"issue":"10","key":"15070_CR49","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1074\/jbc.275.10.7337","volume":"275","author":"M Schuler","year":"2000","unstructured":"Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, Green DR. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J Biol Chem. 2000;275(10):7337\u201342.","journal-title":"J Biol Chem"},{"issue":"5","key":"15070_CR50","doi-asserted-by":"publisher","first-page":"jcs237453","DOI":"10.1242\/jcs.237453","volume":"133","author":"J Blagih","year":"2020","unstructured":"Blagih J, Buck MD, Vousden KH. p53, cancer and the immune response. J Cell Sci. 2020;133(5):jcs237453.","journal-title":"J Cell Sci"},{"issue":"12","key":"15070_CR51","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1586\/14737140.2013.859074","volume":"13","author":"EJ Jabbour","year":"2013","unstructured":"Jabbour EJ, Cortes JE, Kantarjian HM. Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia. Expert Rev Anticancer Ther. 2013;13(12):1433\u201352.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"19","key":"15070_CR52","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.3390\/cancers13194820","volume":"13","author":"R Alves","year":"2021","unstructured":"Alves R, Gon\u00e7alves AC, Rutella S, Almeida AM, De Las Rivas J, Trougakos IP, Sarmento Ribeiro AB. Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014from molecular mechanisms to clinical relevance. Cancers. 2021;13(19):4820.","journal-title":"Cancers"},{"issue":"3","key":"15070_CR53","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.str.2016.02.002","volume":"24","author":"N Alam","year":"2016","unstructured":"Alam N, Zimmerman L, Wolfson Noah A, Joseph Caleb G, Fierke Carol A, Schueler-Furman O. Structure-Based identification of HDAC8 Non-histone substrates. Structure. 2016;24(3):458\u201368.","journal-title":"Structure"},{"key":"15070_CR54","doi-asserted-by":"crossref","unstructured":"Kim JY, Cho H, Yoo J, Kim GW, Jeon YH, Lee SW, Kwon SH. Pathological Role of HDAC8: Cancer and Beyond. Cells 2022, 11(19).","DOI":"10.3390\/cells11193161"},{"key":"15070_CR55","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3389\/fcell.2020.00844","volume":"8","author":"M Spreafico","year":"2020","unstructured":"Spreafico M, Gruszka AM, Valli D, Mazzola M, Deflorian G, Quint\u00e8 A, Totaro MG, Battaglia C, Alcalay M, Marozzi A. HDAC8: a promising therapeutic target for acute myeloid leukemia. Front Cell Dev Biology. 2020;8:844.","journal-title":"Front Cell Dev Biology"},{"issue":"5","key":"15070_CR56","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.stem.2015.08.004","volume":"17","author":"J Qi","year":"2015","unstructured":"Qi J, Singh S, Hua WK, Cai Q, Chao SW, Li L, Liu H, Ho Y, McDonald T, Lin A, et al. HDAC8 Inhibition specifically targets Inv(16) acute myeloid leukemic stem cells by restoring p53 acetylation. Cell Stem Cell. 2015;17(5):597\u2013610.","journal-title":"Cell Stem Cell"},{"key":"15070_CR57","first-page":"100097","volume":"7","author":"MM Yusif","year":"2023","unstructured":"Yusif MM. Targeting cancers and metabolic disorders: the prospects of combining HDAC8 inhibitor and activator. Eur J Med Chem Rep. 2023;7:100097.","journal-title":"Eur J Med Chem Rep"},{"issue":"11","key":"15070_CR58","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1159\/000540247","volume":"102","author":"H Morishita","year":"2024","unstructured":"Morishita H, Otsuka R, Murakami K, Endo S, Toyozumi T, Matsumoto Y, Shiraishi T, Iida S, Makiyama T, Nishioka Y, et al. SIRT1 promotes chemoradiotherapy resistance in esophageal squamous cell carcinoma. Oncology. 2024;102(11):960\u20138.","journal-title":"Oncology"},{"issue":"1","key":"15070_CR59","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-022-01257-8","volume":"7","author":"QJ Wu","year":"2022","unstructured":"Wu QJ, Zhang TN, Chen HH, Yu XF, Lv JL, Liu YY, Liu YS, Zheng G, Zhao JQ, Wei YF, et al. The Sirtuin family in health and disease. Signal Transduct Target Ther. 2022;7(1):402.","journal-title":"Signal Transduct Target Ther"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15070-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-15070-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-15070-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:04:55Z","timestamp":1761735895000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-15070-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["15070"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-15070-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"26 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Research Ethics Committee at the Deputy of Research of Islamic Azad University approved the study protocol (IR.IAU.PS.REC.1402.013). All the methods included in this study are in accordance with the declaration of Helsinki. Written informed consent was obtained from all participants in the study before blood collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1665"}}